Meneni Srinivasarao, Ott Ingo, Sergeant Craig D, Sniady Adam, Gust Ronald, Dembinski Roman
Department of Chemistry and Center for Biomedical Research, Oakland University, 2200 N. Squirrel Rd., Rochester, MI 48309-4477, USA.
Bioorg Med Chem. 2007 Apr 15;15(8):3082-8. doi: 10.1016/j.bmc.2007.01.048. Epub 2007 Feb 1.
Starting with 5-iodo-2'-deoxyuridine, a series of 5-alkynyl-2'-deoxyuridines (with n-propyl, cyclopropyl, 1-hydroxycyclohexyl, p-tolyl, p-tert-butylphenyl, p-pentylphenyl, and trimethylsilyl alkyne substituents) have been synthesized via the palladium-catalyzed (Sonogashira) coupling reaction followed by a simplified isolation protocol (76-94% yield). The cytotoxic activity of modified nucleosides against MCF-7 and MDA-MB-231 human breast cancer cells has been determined in vitro. 5-Ethynyl-2'-deoxyuridine, the only nucleoside in the series containing a terminal acetylene, is the most potent inhibitor with IC(50) (microM) 0.4+/-0.3 for MCF-7 and 4.4+/-0.4 for MDA-MB-231.
从5-碘-2'-脱氧尿苷开始,通过钯催化(Sonogashira)偶联反应,随后采用简化的分离方案(产率76 - 94%),合成了一系列5-炔基-2'-脱氧尿苷(具有正丙基、环丙基、1-羟基环己基、对甲苯基、对叔丁基苯基、对戊基苯基和三甲基硅烷基炔取代基)。已在体外测定了修饰核苷对MCF-7和MDA-MB-231人乳腺癌细胞的细胞毒性活性。5-乙炔基-2'-脱氧尿苷是该系列中唯一含有末端乙炔的核苷,是最有效的抑制剂,对MCF-7的IC(50)(微摩尔)为0.4±0.3,对MDA-MB-231为4.4±0.4。